Biocon shares rose 9% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab.

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

International brokerage Jefferies has upgraded its rating on drugmaker Biocon to 'hold' citing positive newsflow around the regulatory approval of its Bengaluru manufacturing unit. Building on the ...

Save your favourite. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement.

Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.) ...

India's Biocon has partnered with US-based Mylan to sell Indian-made biogenerics globally. Bangalore-based Biocon sees the collaboration with Mylan, the world's third-largest generics producer ...

Biocon stock price today: Shares of Kiran Mazumdar Shaw-led Biocon extended gains to settle five per cent higher on Tuesday, December 24, after the United States Food and Drug Administration ...